Aprepitant
- TRADE NAME: Emend (Merck)
- INDICATIONS: Prevention of postoperative and chemotherapy induced nausea and vomiting
- CLASS: Antiemetic, CYP3A4 inhibitor, Neurokinin 1 receptor antagonist
- HALF-LIFE: 9–13 hours
Alprazolam, Antifungal agents, Astemizole, Avanafil, Betamethasone, Carbamazepine, Cisapride, Clarithromycin, Colchicine, Conivaptan, Corticosteroids, CYP2C9 substrates, CYP3A4 inducers or inhibitors, Dasatinib, Deferasirox, Dexamethasone, Diltiazem, Docetaxel, Eplerenone, Estrogens, Everolimus, Fentanyl, Grapefruit Juice, Halofantrine, Ifosfamide, Imatinib, Irinotecan, Itraconazole, Ketoconazole, Lumateperone, Methylprednisolone, Midazolam, Mifepristone, Naldemedine, Nefazodone, Neratinib, Olaparib, Oral Contraceptives, Paroxetine Hydrochloride, Phenobarbital, Phenytoin, Pimecrolimus, Pimozide, Progestins, Ranolazine, Rifampin, Rifamycin derivatives, Rifapentine, Ritonavir, Salmeterol, Saxagliptin, St John's Wort, Telithromycin, Terfenadine, Tolbutamide, Tolvaptan, Trabectedin, Triamcinolone, Troleandomycin, Vinblastine, Vincristine, Voriconazole, Warfarin
PREGNANCY CATEGORY: N/A
Insufficient evidence to inform drug-associated risk
Fosaprepitant is a prodrug of aprepitant for injection.
Aprepitant treatment is given along with a 5-HT3-receptor antagonist and dexamethasone.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of aprepitant in the Informa Healthcare journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
